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Introduction. Positron emission tomography (PET) is increasingly applied for infection imaging using [18F]FDG as tracer, but
uptake is unspecific. The present study compares the kinetics of [18F]FDG and three other PET tracers with relevance for infection
imaging. Methods. A juvenile porcine osteomyelitis model was used. Eleven pigs underwent PET/CT with 60-minute dynamic
PET imaging of [18F]FDG, [68Ga]Ga-citrate, [11C]methionine, and/or [11C]donepezil, along with blood sampling. For infectious
lesions, kinetic modelling with one- and two-tissue-compartment models was conducted for each tracer. Results. Irreversible
uptake was found for [18F]FDG and [68Ga]Ga-citrate; reversible uptake was found for [11C]methionine (two-tissue model) and
[11C]donepezil (one-tissue model). The uptake rate for [68Ga]Ga-citrate was slow and diffusion-limited. For the other tracers, the
uptake rate was primarily determined by perfusion (flow-limited uptake). Net uptake rate for [18F]FDG and distribution volume for
[11C]methionine were significantly higher for infectious lesions than for correspondingly noninfected tissue. For [11C]donepezil in
pigs, labelled metabolite products appeared to be important for the analysis. Conclusions. The kinetics of the four studied tracers in
infection was characterized. For clinical applications, [18F]FDG remains the first-choice PET tracer. [11C]methionine may have a
potential for detecting soft tissue infections. [68Ga]Ga-citrate and [11C]donepezil were not found useful for imaging of osteomyelitis.
1. Introduction
Positron emission tomography (PET) allows imaging of
molecular uptake but is dependent on the availability of
tracers with uptake related to the investigated disease. For
infection imaging, [18F]FDG is useful [1], but a drawback is
the nonspecific uptake of [18F]FDG in metabolically active
tissues (brain, muscles, etc.) [2].
We previously reported on static PET imaging in a
porcine osteomyelitis model with a series of tracers that have
been proposed for infection imaging [3–5]. In those reports,
we concluded that the performance of [18F]FDG for locating
infection was superior to the other tracers studied. However,
our static imaging shows only the uptake at a given (typically
late) time interval.
In the present paper, we elaborate on those studies
[3–5] by including data from dynamic PET imaging of
the same animals (based on the same tracer injections),
using kinetic analysis to compare [18F]FDG with [68Ga]Ga-
citrate, [11C]methionine (l-[11C-methyl]methionine), and
[11C]donepezil ([5-11C-methoxy]donepezil) as infection trac-
ers. Dynamic imaging allows for a more detailed study of the
uptake and release of tracers, whichmay contribute to a better
understanding of the underlying physiology and also help
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in determining the optimal time for static imaging. Blood
perfusion results from dynamic imaging of [15O]water in the
same animals have already been reported [6].
Gamma-camera imaging (scintigraphy or SPECT) of
infection is sometimes performed with [67Ga]Ga-citrate.
However, image quality is suboptimal and the radiation dose
from 67Ga is high. The positron-emitter 68Ga allows PET
imaging, which has a better spatial resolution and a higher
detection efficiency than standard gamma-camera imaging.
Furthermore, the shorter half-life of 68Ga (67.7min versus
78 hours for 67Ga) reduces the radiation dose. In the body,
the Ga3+ ion acts as an analogue of iron (Fe3+), associating
with transferrin; for more details, see [7]. Preliminary studies
on [68Ga]Ga-citrate in rats [8] and patients [9, 10] reported
promising results.
Methionine is a naturally occurring essential amino acid.
It can be labelled with the positron-emitter 11C to obtain the
chemically identical PET tracer [11C]methionine. Methion-
ine (natural or labelled) is transported into cells via the L-
type amino acid transporter 1. It is crucial for the formation of
proteins and is involved in the synthesis of phospholipids.The
accumulation of methionine therefore reflects amino acid
transport and protein synthesis. During cell replication, the
demand for essential amino acids increases, as do protein
and phospholipid synthesis. Although primarily used to
detect malignant tumours [11], methionine is known from
brain studies to accumulate in inflammatory tissue [12, 13].
Furthermore, a high uptake of [11C]methionine has been
observed after acute myocardial infarction, indicating that
this tracer may be a good marker of inflammatory reactions
during the phase of tissue repair [14].
Donepezil is a reversible inhibitor of acetylcholinesterase
(AChE), the break-down enzyme of acetylcholine (ACh)
[15]. ACh and AChE are primarily known as constituents
in cholinergic neuronal signalling pathways, but immune
cells have been shown to use ACh as a paracrine signalling
molecule [16], and AChE and cholinergic receptors are
upregulated in immune cells when exposed to phytohaemag-
glutinin [17]. It was recently shown that the AChE ligand
[11C]donepezil accumulates at sites of bacterial infection,
suggesting that cholinergic PET imaging may have potential
in the detection of inflammation and infections [18].
Therefore, we investigated the uptake processes of these
PET tracers in order to determine their clinical potential
in infection imaging in relation to both osteomyelitis and
soft tissue infection. We hypothesized that (1) categorization
of tracers into those having either reversible or irreversible
uptake in infectious lesions is possible and (2) perfusion
effects on tracer accumulation can be estimated. Finally, we
wanted to estimate the optimal time points for static imaging
of the tracers.
2. Materials and Methods
2.1. Porcine Osteomyelitis Protocol. The protocol for inducing
osteomyelitis in domestic pigs has been described in detail
elsewhere [3, 19–21]. Briefly, osteomyelitis was induced in
the right hind limb of juvenile Danish Landrace × Yorkshire
female pigs by intra-arterial injection of S. aureus (porcine
strain S54F9). The injection was performed into the right
femoral artery, allowing for selective infection of this hind
limb while leaving the contralateral left hind limb as a
noninfected control. Osteomyelitis was allowed to develop
for one week, after which the pig was scanned and then
euthanized. If a pig reached predefined humane endpoints,
it was then euthanized (and not scanned). A refinement
of the model, combining reduced body weight of the pigs
(from 40 kg to 20 kg) with administration of penicillin at the
onset of the first clinical signs of disease, proved effective in
reducing systemic infection [21].
We attempted to prolong the infection period from one
to two weeks, for the purpose of developing more chronic
lesions, and managed to scan one pig two weeks after
inoculation (pig number 5 of the 11 scanned pigs described
below). However, 4 out of 5 pigs planned for scanning with
the prolonged protocol had to be prematurely euthanized due
to humane endpoints, so we returned to the subacute one-
week pig protocol.
The animal protocol was approved by the Danish Ani-
mal Experimental Board, journal number 2012-15-2934-
00123, and all procedures followed the European Directive
2010/63/EU on the protection of animals used for scientific
purposes.
2.2. Animals and Lesions. Eleven juvenile female domestic
pigs were scanned. Pigs number 1–4 had body weights of
39–42 kg (initial model) and pigs number 5–11 had body
weights of 19–23 kg (refined model). Blood perfusion in
the lesions in these pigs has been described previously [6],
including 17 osteomyelitic (OM) lesions and 8 soft tissue
(ST) lesions, with volume of interest (VOI) drawing primarily
based on computed tomography (CT) scans. Other OM
lesions were also found in pedal bones but were too small for
robust volume of interest (VOI) drawing.
In the present paper, the kinetics of [18F]FDG, [68Ga]Ga-
citrate, [11C]methionine, and [11C]donepezil were studied
and modelled in the same 17 OM lesions and 8 ST lesions,
with VOIs redrawn on the CTs from the dynamic PET/CT
scans of these tracers. Not all tracers were used in all pigs,
and the limitations set by the PET scanner field of view (FOV,
further described below) resulted in not all lesions being
dynamically scanned in all pigs. An overview is given in
Table 1.
We have previously reported some data on the character-
ization of the lesions evolving from S. aureus inoculation in
these pigs, including themethods used for bacteriological and
immunohistochemical (IHC) identification of bacteria [3–5].
Generally, the lesions observed in the pigs were considered
to be caused by infection associated with the inoculated S.
aureus if the bacterial culture and/or S. aureus specific IHC
staining confirmed the presence of S. aureus in one or several
of the lesions within each individual pig (results not shown).
2.3. Dynamic PET Scans. PET scans were carried out at the
Department of Nuclear Medicine & PET Centre (Aarhus
UniversityHospital), and at Department of NuclearMedicine
(AalborgUniversityHospital), with the pigs transported from
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Table 1: Pig ID numbers (1–11) for different tracers and lesionsa.
Tracer Dynamic data available Osteomyelitic (OM) lesions
b
Soft tissue (ST) lesionsb
Proximal femur Distal femur Proximal tibia Distal tibia
[15O]water [6] 1–11 1 1, 5–10 1, 6–10 7, 8, 10 1, 2, 4c, 8–11
[18F]FDG 1–7, 9, 11 1 5–7 6, 7, 9 7 1, 4, 9, 11
[68Ga]Ga-citrate 1–5 1 5 — — 1, 2, 4
[11C]methionine 1–10 1 1, 5–10 1, 6–10 7, 8, 10 1, 2, 4c, 8–10
[11C]donepezil 5–7, 9, 10 — 5–7, 9, 10 6, 7, 9, 10 7, 10 9, 10
aNumbering as presented in the [15O]water paper [6]. bThe[15O]water paper presents an exhaustive list of the lesions studied. In pig number 3, inoculation
failed to produce infection [3]. cTwo soft tissue lesions within the FOV (pig number 4).
(a) (b)
Figure 1: Two fixation devices for the pigs were produced from large plastic tubes, with a distance between the arches of either 15 or 21 cm,
corresponding to the scanner FOVs. Assuming correct positioning of the device in the scanner, the arches made it visually clear where the
FOV of the PET scan was located, thereby facilitating optimal positioning in the scanner. The fixation device also facilitated symmetric limb
positioning and the avoidance of limb movement during the long scan sessions. (a) The 21 cm FOV fixation device. (b) Pig number 6 in the
device.
one hospital to the other. The PET scans at Aarhus included
the 11C-labelled tracers in pigs number 1–10 and [18F]FDG in
pig number 11. The PET scans at Aalborg included [68Ga]Ga-
citrate in pigs number 1–5 and [18F]FDG in pigs number 1–10.
At Aarhus, the PET data were acquired on a Biograph
TruePoint 64 PET/CT scanner (Siemens, Erlangen, Ger-
many). The scan field covered 21 cm in the axial direction
and was positioned over the pelvic region and the hind limbs.
The imageswere reconstructedwith anOSEMalgorithmwith
resolution recovery (TrueX, Siemens). The reconstruction
parameters were 6 iterations, 21 subsets, 336 × 336 matrix in
109 slices, voxel size 2 × 2 × 2mm3, and a 2mm Gaussian
filter. The spatial resolution of the reconstructed images was
approximately 4mm.
At Aalborg, the PET data were acquired on a GE VCT
Discovery 64 PET/CT scanner (GE Healthcare, USA). The
scan field covered 15 cm in the axial direction and was
positioned over the pelvic region and the hind limbs. The
images were reconstructed with an OSEM algorithm without
resolution recovery (3D Vue Point, GE). The reconstruction
parameters were 2 iterations, 28 subsets, 128 × 128 matrix in
47 slices, voxel size 5.5 × 5.5 × 3.3mm3, and a 6mmGaussian
filter.
On both scanners, image reconstruction included decay-
correction to the start of scanning and attenuation-correction
based on CT scanning.
For all tracers, the pigs were dynamically PET scanned for
60 minutes in 23 frames: 8 × 15 s, 4 × 30 s, 2 × 60 s, 2 × 120 s, 4
× 300 s, and 3 × 600 s. For [68Ga]Ga-citrate, the animals were
scanned for an additional 6× 600 s (i.e., 120minutes total scan
time in 29 frames). After each of the dynamic scans, the pigs
were statically scanned; the static PET/CT scans have been
described in previous papers [3–5] and will not be further
discussed here.
The pigs were scanned in dorsal recumbency (supine
position). The hind limbs were positioned for the entire hind
limbs and pelvis to be within the axial field of view (FOV) of
the scanner. This was, however, not always possible; in par-
ticular, the 15 cm FOV at the Aalborg scanner (versus 21 cm
FOV at the Aarhus scanner) was a limitation. To optimize the
fixation position to the scanner FOV, custom-made fixation
devices were used for pigs number 6–11 (Figure 1).
2.4. Blood Samples. Blood samples were drawn from the
carotid artery at predetermined time points as listed below.
The samples were manually drawn, and small variations
occurred; the actual time of each sample was recorded. The
samples were centrifuged to obtain plasma samples, which
were counted in calibrated gamma-counters.
At Aarhus, plasma samples were counted in a Packard
Cobra gamma counter. An energy window from 400 to
1400 keV was used. No signs of interference between consec-
utively administered radionuclides were seen in the plasma
curves.
At Aalborg, plasma samples and full-blood samples were
counted in a Wizard 2480 gamma counter (PerkinElmer,
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Turku, Finland). To avoid interference from remnants of 111In
from 111In-leukocytes (used in the same animals [3]), an
energy window from 450 to 1200 keV was used [22].
In the 40 kg pigs (pigs number 1–4), 37 blood samples
were drawn per tracer: every 5 seconds for 1 minute (12
samples), at 70, 80, 90, 100, 120, 140, 160, 180, 210, 240, 270,
and 300 seconds (12 samples), and at 6, 7, 8, 9, 10, 15, 20, 25,
30, 35, 40, 50, and 60 minutes (13 samples). For [68Ga]Ga-
citrate, blood samples were also drawn at 75, 90, 105, and 120
minutes (four samples), for a total of 41 blood samples.
In the 20 kg pigs (pigs number 5–11), the number of blood
sampleswas reduced to 26 samples per tracer: every 5 seconds
for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240,
and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40, and
55 minutes (8 samples).
For [11C]methionine and [11C]donepezil, additional
blood samples were drawn for metabolite analysis: at 2, 5, 10,
15, 25, and 40 minutes in the 40 kg pigs, and at 2, 5, 10, 20, 30,
40, and 55 minutes in the 20 kg pigs.
2.5. Input Function. The blood plasma rather than full blood
was considered to be the reference fluid for tracer delivery
(corresponding to equilibration between blood cells and
plasma being slow compared to single-passage time of blood
in the tissue). Accordingly, all input functions were based on
plasma samples.
For both [18F]FDG and [68Ga]Ga-citrate, the decay-
corrected plasma sample datawere used as the input function.
Nometabolite correctionwas performed for these two tracers
because metabolite products are not expected to be found in
the blood. [18F]FDG is phosphorylated within the cells, but
the resulting (radioactive) metabolite is trapped within the
cells [23]. Regarding [68Ga]Ga-citrate, theGa-citrate complex
quickly dissociates into Ga3+ and citrate3− within the blood,
but the gallium ion attaches to transferrin (making [68Ga]Ga-
transferrin the actual tracer). Therefore, free gallium is not
found in the blood [24].
For [11C]methionine and [11C]donepezil, metabolite cor-
rection was performed. A fractionated HPLC analysis was
used to separate the metabolites from the parent tracer,
and counting was used to determine the fraction of activity
representing the parent tracer. Based on the obtained data
points, Hill-type fraction curves were fitted:
𝑓 (𝑡) = 1 − (1 − 𝑎) 𝑡𝑏𝑐 + 𝑡𝑏 , (1)
where 𝑡 is the sampling time (seconds postinjection). The
function starts at 𝑓(0) = 1 (thus assuming no metabolism
before injection) and has an asymptotic value 𝑓(∞) = 𝑎.
The parameters 𝑎, 𝑏, and 𝑐 were fitted for both tracers in the
individual pigs.
In the following text, the uncorrected input function will
denote the activity concentration (decay-corrected Bq/mL)
from plasma samples and themetabolite-corrected input func-
tion will denote 𝑓(𝑡) times the uncorrected input function.
2.6. Determination of the Delay-Correction. The measured
input function can be biased by delay and dispersion effects
due to the differences in distance between the blood sampling
site (carotid artery) and the infection sites in the hind limbs.
Such a delay can be determined by applying a series of
possible delay-correction values, fitting the data with each
value, and selecting the delay-correction resulting in the best
fit [25].
We applied this procedure for each tracer in each animal,
using input function offsets from −60 s to +60 s in 1-second
steps. This was done using the uncorrected plasma data
for the input function, and fitting a reversible two-tissue
compartment model (rev2TCM in Figure 2; the models are
further discussed below) to the first 300 s of the full field-
of-view data. Using full FOV data ensures that the statistical
noise is low. Restricting this fit to the early data has several
advantages. First, this focuses on the part of the study where
the input function changes fast and the delay therefore is
important. Second, this means that physiological differences
in uptake (e.g., bladder versus nonbladder, infection versus
noninfection) will only have had little time to manifest; thus
the full FOV data will be dominated by the bolus passage
in this anatomical part of the animal, rather than by a mix
of physiologies. Third, the possible metabolism effects will
not yet dominate the input function, for which reason the
uncorrected input function can be considered representative,
even if the tracer over time is metabolized.
2.7. Kinetic Models. Relatively little literature exists on tracer
kinetics in infections for the tracers investigated in this work.
Rather than imposing a specific model on these tracers, we
examined the applicability of three different models for each
tracer (Figure 2).
Physiologically, the 1TCM corresponds to the tracer
entering and leaving the tissue with no binding or other spe-
cific uptake. The irr2TCM describes uptake and irreversible
trapping of the tracer or metabolites (e.g., phosphorylated
[18F]FDG).The rev2TCM corresponds to uptake in the tissue
followed by reversible binding (or reversible metabolism) of
the tracer.
In all of the models, the 𝐾1 rate constant describes the
first-pass uptake of tracer, equal to the product of perfusion
and the first-pass extraction fraction. We report 𝐾1 in units
of mL/min/100 cm3, that is, mL uptake per minute per
100 cm3 of tissue. The other rate constants (𝑘2, 𝑘3, and 𝑘4,
all with unit min−1) describe how rapid the concentration
in a compartment changes due to a given process (excretion,
binding, andmetabolism in the tissue).The blood fraction𝑉𝑏
is the fraction of measured PET signal that originates from
the blood in the vascular bed.
Formodelswith irreversible uptake, the net uptake rate𝐾𝑖
(same unit as 𝐾1) represents the effective irreversible uptake
from the input. Whereas𝐾1 represents the rate of immediate
(first-pass) uptake of tracer,𝐾𝑖 can similarly be interpreted as
the rate of long-termuptake. For the irr2TCM, the theoretical
net uptake rate is
𝐾𝑖 = 𝐾1 ⋅ 𝑘3𝑘2 + 𝑘3 (for irr2TCM) . (2)
The net uptake rate may also be determined as the slope of a
Patlak plot [26, 27].
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Figure 2: Kinetic models. From top to bottom: 1-tissue compartment model (1TCM), 2-tissue compartment model with irreversible uptake
(irr2TCM), and 2TCM with reversible uptake (rev2TCM). The rate constants were fitted as 𝐾1 (unit mL/min/cm3 or mL/min/100 cm3), the
ratio 𝐾1/𝑘2 (unit mL/cm3), 𝑘3 (unit min−1), and the ratio 𝑘3/𝑘4 (no unit). Also the blood fraction 𝑉𝑏 was fitted.
For models with reversible uptake, the distribution vol-
ume (DV, unitmL/cm3) is the ratio of the tissue concentration
to the “input” concentration, once a steady-state has been
reached, that is, the volume of “input” needed to account
for the activity in 1 cm3 of tissue [28]. Although not being
an uptake rate, DV may be used as an indicator of the
degree of long-term uptake. For the 1TCM and rev2TCM, the
theoretical distribution volumes are
DV = 𝐾1𝑘2 (for 1TCM) (3)
DV = 𝐾1𝑘2 ⋅ (1 +
𝑘3
𝑘4) (for rev2TCM) . (4)
The distribution volume of reversible uptake may also be
determined as the slope of a Logan plot [29, 30].
2.8. Weighting of the PET Data in Modelling. Theoretically,
least-squares fitting is optimal with weights proportional to
1/𝜎2 where 𝜎2 is the variance of the noise. With 𝑁 counts
(Poisson distributed) during a frame length 𝐿, the count rate
𝑅 = 𝑁/𝐿 has variance:
𝜎2 (𝑅) = 𝑁𝐿2 =
𝑅
𝐿 . (5)
After decay-correction:
𝑅dc = dcf × 𝑅
𝜎2 (𝑅dc) = dcf2 × 𝑅𝐿 = dcf ×
𝑅dc
𝐿 ,
(6)
where dcf is the decay-correction factor, calculated from the
radionuclide half-life and frame time interval. For weighting
purposes, it can be well approximated by using the mid-time
of the frame:
dcf = 2𝑡/𝑇1/2 = exp (𝜆𝑡) . (7)
Seemingly, optimal weighting should be 1/𝜎2 = 𝐿/𝑅 for non-
decay-corrected data and 1/𝜎2 = 𝐿/(dcf × 𝑅dc) for decay-
corrected data.
However, the count rate (or the activity concentration)
is known only from a measurement that includes noise.
In a simulation study, Thiele and Buchert [31] found that
noise in the weighting factors can severely degrade parameter
estimation and should therefore be avoided. Consistent with
the weighting that gave the best results in that study, we
used the following noise-free weighting factors for the decay-
corrected PET data:
𝑤 = 𝐿
dcf
= 𝐿 × exp (−𝜆𝑡) . (8)
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These weights correctly include the effects of decay and the
large differences in frame length (from 15 to 600 seconds).
The weights are noise-free, at the cost of ignoring the
statistical effects from variation in tracer concentration due
to kinetics.
This approximation (weights not fully reflecting 1/𝜎2) is
unlikely to be a problem. A simulation study by Yaqub et al.
[32] found that kinetic modelling of PET data was reasonably
robust against some misrepresentation of the variance in
(noise-free) weighting, with only severe misrepresentation
being a problem.
2.9. Modelling. For each tracer in each model (1TCM,
irr2TCM, and rev2TCM), the fitted parameters were
determined using least-squares fitting with the weighting
described above. Additionally, Patlak plots and Logan
plots were computed, based on the data from 10 minutes
postinjection (p.i.) and onwards.
For [11C]methionine and [11C]donepezil, this procedure
was performed twice: using an uncorrected input function
and using a metabolite-corrected input function. For these
two tracers, modelling was restricted to data from the first 40
minutes (out of 60 minutes), as metabolite data were in many
cases incomplete for later frames.
Modelling was performed using software acquired from
the Turku PET Centre website [33]. The parameter 𝑘2 was
fitted as the ratio 𝐾1/𝑘2 (corresponding to the distribution
volume of the first compartment). In the rev2TCM, the
parameter 𝑘4 was fitted as the ratio 𝑘3/𝑘4 (corresponding to
the binding potential BP if the first and second compartments
are considered to represent unspecific and specific uptake,
resp.).
2.10. Evaluation. In addition to visual inspection of the fits,
the three models were compared with the corrected Akaike
Information Criterion (AICc), which rewards a good fit but
punishes the use of a model with many fitting parameters.
For a given data set, AICc favours the model resulting in the
lowest AICc value [34, 35].
For the determination of uptake as reversible or irre-
versible, the Patlak plot also was considered. If the uptake is
reversible (i.e., not irreversible), the Patlak plot will eventually
approach a constant value. Therefore, the linearity of the
Patlak plot with a nonzero slope can be used as a test for
irreversible uptake.
All these results are based on plasma input functions.
To compare with perfusion, previously published results for
blood perfusion in the same animals [6] were transformed
into plasma perfusion by the formula
plasma perfusion = (1 − haematocrit)
× blood perfusion, (9)
with haematocrit being measured at a time roughly corre-
sponding to the time of the [15O]water PET.
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Figure 3: Representative data and curve fit (see (1)) for the fraction
of nonmetabolized [11C]methionine (from pig number 1).
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Figure 4: Representative data and curve fit (see (1)) for the fraction
of nonmetabolized [11C]donepezil (from pig number 10).
3. Results
3.1. Metabolite Correction. The fraction curves indicated
considerable metabolism of both [11C]methionine (Figure 3)
and [11C]donepezil (Figure 4).
For both [11C]methionine and [11C]donepezil, the
“uncorrected” (i.e., not corrected for metabolism, but
corrected for physical decay) plasma curves showed an
unexpected tendency of slightly rising values after typically
20 minutes. As an example, see the data for [11C]methionine
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Table 2: Evaluation of the fitting models for the investigated tracers and input functions.
Tracer Number of OM +ST foci modelled Plasma input function Visual impression of fit
Linear
Patlak plot Lowest AICc
[18F]FDG 8 + 7 Uncorrected
Good fit of both 2TCM, with rev2TCM
giving only minor improvement over
irr2TCM. Poor fit of 1TCM.
Yes rev2TCM
[68Ga]Ga-citrate 2 + 3 Uncorrected Good fit of both 2TCM, with 1TCMreasonable for some curves. Yes
irr2TCM or
rev2TCM
[11C]methionine 17 + 7
Uncorrected Good fits of rev2TCM. Cases with goodirr2TCM fit (generally low-lying curves). No
See main text
Metab. corr.
For irr2TCM, the fit was improved over the
uncorrected input function. Overall,
rev2TCM appeared best.
Almost
[11C]donepezil 11 + 2
Uncorrected Poor fits for all models. No
See main text
Metab. corr. Good fits with 1TCM, only slightlyimproved by 2TCM (irr or rev).
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Figure 5: Representative sample plasma activity curves for
[11C]methionine (decay-corrected, from pig number 1).The scale of
the vertical axis has been chosen to emphasize the curve tails, at the
cost of truncating the bolus peak (maximum value ∼600 kBq/mL).
Uncorrected input function is the total plasma activity concentra-
tion (grey curve). Metabolite-corrected input function (red curve)
originates as the product of the total plasma activity curve and
the fraction curve (Figure 3). Also shown is the metabolite activity
concentration (blue curve), that is, the difference between the
other two curves. Similar curves were seen for [11C]donepezil (not
shown).
in Figure 5 (the data for [11C]donepezil were similar).
Possible reasons like unresolved background counts, either
from other tracers in the multitracer study or from the
surroundings, were investigated, but no sign of any such
problems was found; for example, blood samples taken
before the arrival of the bolus injection were far below
the level that would cause this background. Therefore, we
conclude that the curves correctly represent the activity
concentration in the plasma. After metabolite correction, the
curves decreased as expected (Figure 5).
3.2. Delay-Correction of Input Function. Each input function
(𝑛 = 26) was individually delay-corrected (but with a com-
mon delay for all lesions in the same scan).Themean ± SD of
the corrections was −4.5 ± 4.1 seconds. A negative correction
corresponds to the tracer arriving earlier to the scanned tissue
(PET data) than to the site of blood sampling (plasma input
data). All individual corrections were numerically smaller
than the initial PET frame length (15 seconds).
3.3. Modelling. The overall results for the different models
are summarized in Table 2, with elaborating comments given
here.
3.3.1. [18F]FDG. Despite the lowest AICc values having been
found for rev2TCM, the irr2TCM appeared visually to give a
reasonable fit for the investigated time range. Example fits are
shown in Figure 6. The Patlak plots (not shown) were linear
with nonzero slopes, indicating the presence of irreversible
uptake. Also, the majority of fitted ratios 𝑘3/𝑘4 were above
2 (median value ∼4 for all VOIs, ∼5 if restricted to infected
side); that is, overall 𝑘4 was considerably lower than 𝑘3. For
these reasons and because irr2TCM has fewer parameters
than rev2TCM, we pragmatically chose to base the further
analysis of [18F]FDG uptake on the irr2TCM. The values of
𝐾1 were overall very similar for irr2TCM and rev2TCM.
3.3.2. [68Ga]Ga-Citrate. Overall, the AICc values indicated
nearly equal quality of fits for irr2TCM and rev2TCM.
Example fits are shown in Figure 7. The Patlak plots were
linear with nonzero slopes. Further analysis will assume the
simplest model: irr2TCM.
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Figure 6: Model fits for [18F]FDG in pig number 6, using 1TCM (a), irr2TCM (b), and rev2TCM (c) models. Red and blue: OM lesion in the
distal femur and the corresponding noninfected bone. Green andmauve: OM lesion in the proximal tibia and the corresponding noninfected
tissue. In this case, modelling was restricted to 0–40 minutes because movement of the right limb occurred in the following frame.
For both [18F]FDG and [68Ga]Ga-citrate, good corre-
spondence was observed between the slope of the Patlak plot
and𝐾𝑖 calculated from the irr2TCM parameters.
3.3.3. [11C]Methionine. The AICc values sometimes favoured
rev2TCM and sometimes favoured irr2TCM, but, frommean
the and median values, rev2TCM was favoured. Visually, the
irr2TCM fit showed a problematic upward trend in the late
part of the fits (Figure 8). Despite the extent of metabolism
during the study (Figure 3), only a small difference was
observed between using the uncorrected or the metabolite-
corrected input function with the rev2TCM: the AICc values
were comparable, the fits were visually very similar, and the
fitted rate parameters 𝐾1, 𝐾1/𝑘2, and 𝑘3 were very similar.
Only the 𝑘3/𝑘4 values differed markedly, being lower for the
corrected than the uncorrected input function. However, the
𝑘3/𝑘4 ratio is important for the distribution volume (see (4)),
and the further analysis of the [11C]methionine data will
assume the rev2TCMmodel with a metabolite-corrected input
function.
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Figure 7: Model fits for [68Ga]Ga-citrate in pig no. 1, using 1TCM (a), irr2TCM (b), and rev2TCM (c) models. Orange and light blue: OM
lesion in the proximal femur and the corresponding noninfected bone. Light green and cyan: ST lesion near the metatarsal bone and the
corresponding noninfected tissue.
3.3.4. [11C]Donepezil. Both the plots and the AICc values
unequivocally favoured fits with ametabolite-corrected input
function (Figure 9). Within these, the AICc values variably
favoured each of the threemodels butwith no obvious pattern
(e.g., not distinguishing infected versus noninfected tissue,
bone versus soft tissue, or high versus low 𝐾1). Visually,
however, the 1TCM (with metabolite-corrected input) fits
well in all cases. A typical fit for the 1TCM is seen in
Figure 9(b). Further analysis of [11C]donepezil will be based
on the 1TCM with a metabolite-corrected input function.
3.4. Perfusion and First-Pass Uptake Rate (𝐾1). The 𝐾1
parameter represents the product of perfusion and the
extraction fraction for the tracer. Thus, plotting 𝐾1 as a
function of perfusion gives a measure of extraction; if the
extraction fraction is independent of perfusion, the plot will
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Figure 8: Model fits for [11C]methionine in pig number 6 (same animal as in Figure 6), using uncorrected plasma data as the input function.
Legend as in Figure 6. Fits with a metabolite-corrected input function (not shown) were visually very similar to the shown fits, although with
a reduced upward trend in the irreversible model (b).
show proportionality between 𝐾1 and perfusion. The blood
perfusion of these lesions in these animals has been described
previously, based on [15O]water PET scans [6]. These data
were transformed into plasma perfusion according to (9).
Figure 10 shows the values of 𝐾1 plotted as a function of
plasma perfusion.Notably, [68Ga]Ga-citrate shows only small
uptake compared to perfusion, that is, a small extraction
fraction.
The paradoxical plot for [11C]donepezil, showing 𝐾1
values that are significantly higher than perfusion (corre-
sponding to >100% extraction), is not a result of using
the simple 1TCM rather than one of the 2TCM models.
Overall, the 𝐾1 data from these models (not shown) were
very similar, in some cases even higher, resulting in very
similar plots (not shown). For further explanations, see
Discussion.
For [18F]FDG, [11C]methionine, and [11C]donepezil, a
paired t-test showed a higher 𝐾1 in the infected (right)
side than in the noninfected (left) side (𝑝 ≤ 0.0001). For
[68Ga]Ga-citrate, no significant difference was found (𝑝 >
0.05).
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Figure 9: Model fits for [11C]donepezil in pig number 6 (same animal as in Figures 6 and 8). Legend as in Figure 6. (a) Using the uncorrected
input function, even the model with the most parameters (rev2TCM) gives a poor fit. (b) Using the metabolite-corrected input function, the
model with the least parameters (1TCM) gives a good fit.
3.5. Irreversible Net Uptake Rate (𝐾𝑖) for [18F]FDG and
[68Ga]Ga-Citrate. For both [18F]FDG and [68Ga]Ga-citrate,
good agreementwas observed between𝐾𝑖 calculated from the
Patlak plots and from the irr2TCMmodel (data not shown).
Figure 11 shows 𝐾𝑖 as a function of plasma perfusion.
Figure 12 compares 𝐾𝑖 in the infected versus correspond-
ing noninfected positions. For [18F]FDG, 𝐾𝑖 values were
significantly higher in the infected lesions than in the cor-
responding noninfected positions (𝑝 < 0.002, paired t-
test). For [68Ga]Ga-citrate, the difference was not statistically
significant (𝑝 > 0.05).
3.6. Distribution Volume (DV) of Reversible Tracers. For
[11C]donepezil fitted with the 1TCM, good agreement was
observed between DV calculated from the Logan plots and
from (3). For [11C]methionine fitted with the rev2TCM, the
agreement was not as good betweenDV from the Logan plots
and from (4); however, the lack of agreement was due to
the rev2TCM giving unrealistically high values in some cases
(e.g., >100mL/cm3), corresponding to cases with high values
of 𝑘3/𝑘4. Excluding these cases, good agreementwas observed
in the DV calculations.
Overall, the slope of the Logan plot was used as a
robust measure of DV. Figure 13 shows DV as a function of
plasma perfusion. Figure 14 compares DV in the infected and
corresponding noninfected locations. For [11C]methionine,
DV was significantly higher in the infected locations (𝑝 =
0.0005), while the minor difference seen for [11C]donepezil
was not significant (𝑝 > 0.05).
4. Discussion
Four very different PET tracers were studied for their poten-
tial asmarkers of infection in a porcinemodel of osteomyelitis
(including associated soft tissue lesions). As noted, the results
from static imaging have been reported earlier [3–5], but
dynamic imaging can provide more information on the
uptake processes, which is not available when the tracer
concentration is measured at only one time interval.
The modelling of PET data is restricted by the length
of the acquisition, the number of data points, and statistical
noise. Therefore, some level of pragmatism is needed when
setting up or choosing amodel. Strictly irreversible uptake (in
the sense of the molecules staying in the body for life) is rare,
but the efflux level from a compartment may be practically
zero relative to the length of the PET acquisition. In the
present study, we attempted to find a level that makes the
models useful for providing information about the uptake
process while accepting a level of pragmatism to distinguish
“practically irreversible” from “practically reversible” uptake.
4.1. [18F]FDG. For the kinetic modelling of [18F]FDG, the
two classical models are the irr2TCM by Sokoloff et al. [36]
and the rev2TCM by Phelps et al. [37]. In both models,
the second tissue compartment represents the metabolite
product [18F]FDG-6-phosphate, and in the latter model 𝑘4 >0 represents dephosphorylation back to [18F]FDG. Relative to
infection, the kinetic modelling of [18F]FDG uptake appears
only to have been performed in lung studies (reviewed in
[38]) and in a single study of an acute viral infection [39]. All
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Figure 10: First-pass uptake 𝐾1 as a function of plasma perfusion, shown along with the identity line (𝑦 = 𝑥). The black squares represent
infection foci and the grey circles represent the corresponding noninfected positions.The plots include both bone and soft tissue data.Thedata
for [68Ga]Ga-citrate did not correlate with perfusion (𝑅2 = 0.03). For [11C]donepezil, all data points are above the identity line, paradoxically
corresponding to an extraction fraction above 100%. See Discussion.
of these studies focus on irreversible uptakemodels, generally
the irr2TCM, although some lung studies included a separate
reversible compartment for uptake in pulmonary oedema
[38, 40].
In our porcine osteomyelitis model, the uptake of
[18F]FDG was found to be (practically) irreversible, with
a reasonable fit by the irr2TCM. Accordingly, the level of
uptake was evaluated based on the irreversible net uptake
rate,𝐾𝑖, in almost all cases showing elevated uptake in lesions
compared to healthy tissue, for both OM and ST lesions
(Figure 12).The correlationwith perfusion seen for both first-
pass uptake (Figure 10) and net uptake (Figure 11) indicates
uptake of [18F]FDG to be more flow-limited than diffusion-
limited.
4.2. [68Ga]Ga-Citrate. Dynamic PET studies of [68Ga]Ga-
citrate and [68Ga]Ga-transferrin have been published before
[8, 41, 42], but the present study appears to be the first to
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Figure 11: Irreversible uptake 𝐾𝑖 as a function of plasma perfusion, for the tracers showing irreversible uptake: [18F]FDG (a) and [68Ga]Ga-
citrate (b). Black squares represent infection foci and grey circles corresponding to noninfected positions (compare with Figure 10).
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Figure 12: Comparison of irreversible net uptake rate 𝐾𝑖 in infected (right hind limb) versus noninfected (left hind limb) positions. Bone is
represented by blue squares and soft tissue by red circles. The line is the identity line (𝑦 = 𝑥). (a) shows [18F]FDG and (b) shows [68Ga]Ga-
citrate; note the difference in scales.
include kinetic modelling. As noted by Kumar and Boddeti
[43], no literature is available on the early imaging times of
[67Ga]Ga-citrate SPECT. We found the uptake of 68Ga to be
well described by the irr2TCM (Figure 7). However, first-
pass uptake (𝐾1) of 68Ga was small compared to that of the
other tracers, indicating a very small extraction fraction with
little dependence on perfusion (Figures 10 and 11), that is,
diffusion-limited.
The physiological reason for the slow uptake of 68Ga
may be related to the binding of gallium to a large protein
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Figure 13: Distribution volume DV as a function of plasma perfusion, for the tracers showing reversible uptake: [11C]methionine (a) and
[11C]donepezil (b). Legend as in Figure 11.
(transferrin). Uptake will either require extravasation of
the large [68Ga]Ga-transferrin complex or require a two-
step process, such as the release of 68Ga from the protein
before the uptake or the uptake of [68Ga]Ga-transferrin by
leukocytes which then enter tissue [44]. Therefore, even
though bacteria may show increased uptake of gallium due
to its chemical similarities with iron [43], the overall uptake
mechanism appears to be quite slow.
For static imaging, slow uptake favours late imaging.
Physically, the half-life of 68Ga restricts imaging to a few
hours after injection. In a study of lung lesions, Vorster et al.
[10] recommended imaging to start no later than 120 minutes
p.i.
Compared to other 68Ga infection studies [8–10, 41], the
results in the porcine osteomyelitis model (present paper and
[3, 4]) appear disappointing. At the basic level, the tracer
is a Ga3+ ion (with chemical similarities to the Fe3+ ion),
which makes a species difference unlikely. A different reason
may be indicated by Figure 12: maybe the tracer is able to
differentiate infected soft tissue from healthy tissue (despite
the slow uptake rate) but is not suitable for bone infections.
Ma¨kinen et al. [8] did find uptake in bone lesions in a rat
model, but noted as a limitation of the study that their model
“perhaps best simulates osteomyelitis arising from grossly
contaminated long-bone fractures.” In contrast, the porcine
osteomyelitis model represents haematogenous osteomyelitis
without bone trauma.
4.3. [11C]Methionine. The modelling of [11C]methionine
uptake required a rev2TCM. For comparison, Fischman et
al. [45] described the muscle uptake of [11C]methionine with
a 2TCM, where the second compartment represented the
incorporation of [11C]methionine in tissue proteins, and they
assumed that the degradation rate of labelled protein could
be ignored (corresponding to 𝑘4 = 0 in our notation). That
is, they suggested an irr2TCM rather than rev2TCM. Our
finding of rev2TCMas preferable thus corresponds to protein
degradation being nonnegligible.
Despite the considerable metabolism of [11C]methionine
during the acquisition time (Figure 3), practically only the 𝑘4
rate constant depended on whether modelling was based on
the uncorrected or the metabolite-corrected input function
(with higher 𝑘4 values in the latter case). It appears that the
metabolite products have kinetics quite similar to the original
molecule. The correlation with perfusion seen for both first-
pass uptake (Figure 10) and distribution volume (Figure 13)
indicates uptake of [11C]methionine to be flow-limited.
The unexpected rise in the plasma activity curves after
∼20 minutes (Figure 5) might be explained by a heavy uptake
by metabolizing organs (the liver), followed by a later release
of radioactive metabolite products to the blood pool.
Generally, the distribution volume (DV) for [11C]methi-
onine was higher in the infected tissue than in the nonin-
fected tissue (Figure 14).This difference between infected and
noninfected tissue could point to [11C]methionine having a
role in infection imaging (regardless of the role of perfusion
in causing the distinction). In line with the results from
static imaging [3, 5], the distinction between infected and
noninfected tissue appearedmore clear for soft tissue than for
bone (Figure 14). As indicated by the two already mentioned
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Figure 14: Comparison of the distribution volume DV in infected (right) and noninfected (left) limbs. Bone is represented by blue squares
and soft tissue by red circles. The line is the identity line (𝑦 = 𝑥). (a) shows [11C]methionine, and (b) shows [11C]donepezil.
case reports [12, 13], [11C]methionine could be useful for
brain infection imaging, where [18F]FDG suffers from the
high physiological uptake in healthy brain tissue.
The uptake curves in both infected and noninfected
tissues appear quite stable after approximately 10–15 minutes
(Figure 8), indicating that static imaging could be performed
starting at this time.
4.4. [11C]Donepezil. Metabolite-corrected [11C]donepezil
could be modelled with the 1TCM model. However, the 𝐾1
parameter was systematically higher than plasma (and blood)
perfusion, paradoxically indicating an extraction fraction
above 100% (Figure 10). We consider this to be an indication
that at least one of the radioactive metabolite products of
[11C]donepezil has marked uptake along with the main
tracer. Indeed, Funaki et al. [46] reported that affinity of the
M1 metabolite for AChE is almost as high as the affinity of
donepezil for AChE; the M1 metabolite is radioactive when
the parent tracer is [5-11C-methoxy]donepezil. In a steady-
state study with a regular administration of donepezil,
Meier-Davis et al. [47] found M1 to be relatively more
prominent in minipigs than in humans and rats.
Meier-Davis et al. [47] also found the overall level of
metabolites to be higher in the pigs. This species difference
may explain why we found relatively fast metabolization of
[11C]donepezil (Figure 4), in contrast to the human study
by Hiraoka et al. [48] who saw only minor metabolism
of [11C]donepezil (>85% remaining after 30 minutes) and
therefore did not need metabolite correction. Also, Hiraoka
et al. found the rev2TCM to be unequivocally better than
the 1TCM, while our study finds the distinction less clear. As
noted, however, their input functions were not corrected for
metabolites.
The strong correlation between first-pass uptake and
perfusion (Figure 10) indicates flow-limited uptake of
[11C]donepezil, although the effect is less evident for distri-
bution volume (Figure 13).
Regarding [11C]donepezil as an infection tracer, our data
did show an overall higher first-pass uptake in the infected
lesions and a strong correlation with perfusion (Figure 10),
while theDVwas only slightly higher in the infected sites than
in the corresponding noninfected locations (Figure 14), and
the difference was not statistically significant.
4.5. Limitations. Thepigmodel was developed as a model for
osteomyelitis, for which reason only relatively few soft tissue
lesions were available, limiting the scope of the study as a
general infection study. For [68Ga]Ga-citrate, only relatively
limited data were available.
5. Conclusion
[18F]FDG was reasonably well described by the irr2TCM
(irreversible uptake, three rate constants) for the 60-minute
length studied, and, for both bone and soft tissue, [18F]FDG
showed increased uptake in infected tissue (Figure 12). The
correlation with perfusion indicated that the tracer is mainly
flow-limited.
[68Ga]Ga-citrate was also well described by irrTCM but
showed very little or very slow uptake, which was a limitation
for infection imaging. The difference between infected and
noninfected sites appeared to be higher in soft tissue rather
than bone lesions, but too little data were available to draw
a conclusion (Figure 12). Uptake was slow and diffusion-
limited. To allow time for uptake, “late” imaging is preferable,
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but not so late that the radionuclide has decayed. Imaging at
120 minutes p.i. appears a good compromise.
[11C]methionine needed a rev2TCM (reversible uptake,
four rate constants) for modelling. Despite considerable
metabolism during the 40 minutes modelled, the𝐾1, 𝑘2, and𝑘3 rate constants were only slightly affected if an uncorrected
input function was used, that is, only 𝑘4 was markedly
affected. In a majority of cases, the uptake (measured as
the distribution volume) was elevated in the infected tissue
compared to the noninfected tissue (Figure 14), but the
difference was less than for [18F]FDG (measured as the net
uptake rate, Figure 12). Uptake appeared flow-limited. Based
on the activity curves, imaging at ∼15 minutes p.i. appears
favourable.
[11C]donepezil could be modelled with a 1TCM (revers-
ible uptake, two rate constants) but required metabolite
correction—at least in this juvenile, porcine model. The
uptake of labelled metabolite products appeared to be
nonnegligible. Based on the present study, the uptake of
[11C]donepezil in osteomyelitis seems to depend more on
perfusion (flow-limited) than ondifferences between infected
and noninfected tissues. For soft tissue infection, too few data
were available to draw a conclusion.
Overall, among the studied PET tracers [18F]FDG
showed optimal characteristics for the detection of infec-
tious foci. [68Ga]Ga-citrate and [11C]donepezil were not
found to be useful for imaging of osteomyelitis. For soft
tissue, [11C]methionine and perhaps [68Ga]Ga-citrate may
be applicable to quantify different aspects of inflammatory
or infectious processes, while too few soft tissue data on
[11C]donepezil were available to draw any conclusions.
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